RESUMO
The study was carried out to determine the effect of a combination regimen of a small dose of calcitonin added to conjugated estrogens with medroxyprogesterone acetate on vertebral bone mass in early postmenopausal women. Comparisons were made with groups of women on calcitonin alone, on conjugated estrogens with medroxyprogesterone acetate alone, or on no treatment. The study was carried out over a 2-year period. The results of the study suggest that the combined regimen of calcitonin and estrogens increased vertebral bone mass in early postmenopausal women to a greater extent than calcitonin alone or estrogen alone. Increases in vertebral bone mass of 11.2% after 1 year and 9.2% after 2 years were demonstrated using the combined regimen. Both estrogens alone and calcitonin alone were, however, very effective in preventing rapid bone loss in the postmenopausal women studied.
Assuntos
Densidade Óssea/efeitos dos fármacos , Calcitonina/análogos & derivados , Terapia de Reposição de Estrogênios , Estrogênios Conjugados (USP)/uso terapêutico , Osteoporose Pós-Menopausa/prevenção & controle , Administração Oral , Análise de Variância , Biomarcadores/sangue , Biomarcadores/urina , Calcitonina/administração & dosagem , Calcitonina/farmacologia , Calcitonina/uso terapêutico , Sinergismo Farmacológico , Quimioterapia Combinada , Estrogênios Conjugados (USP)/administração & dosagem , Estrogênios Conjugados (USP)/farmacologia , Feminino , Humanos , Medroxiprogesterona/administração & dosagem , Medroxiprogesterona/farmacologia , Medroxiprogesterona/uso terapêutico , Menopausa , Coluna VertebralRESUMO
A total of 104 postmenopausal women were randomly assigned to different therapeutic regimens: (a) calcitonin, (b) estrogen/progestogen (HRT) plus calcitonin, (c) estrogen/progestogen (HRT), (d) and the control group. The bone mass of the lumbar vertebrae of all patients was assessed with a dual beam photon absorptiometer (Norland GD 153). The 73 patients who completed the 1-yr study showed that postmenopausal bone loss could be prevented by either estrogen/progestogen (HRT) or calcitonin. In addition, the combination of hormonal replacement therapy and calcitonin not only prevented post-menopausal bone loss but resulted in a significant 10% gain in bone mass (P < 0.001).
Assuntos
Densidade Óssea/efeitos dos fármacos , Calcitonina/análogos & derivados , Terapia de Reposição de Estrogênios , Estrogênios Conjugados (USP)/administração & dosagem , Acetato de Medroxiprogesterona/administração & dosagem , Osteoporose Pós-Menopausa/prevenção & controle , Absorciometria de Fóton , Análise de Variância , Calcitonina/administração & dosagem , Calcitonina/farmacologia , Calcitonina/uso terapêutico , Quimioterapia Combinada , Estrogênios Conjugados (USP)/farmacologia , Estrogênios Conjugados (USP)/uso terapêutico , Feminino , Humanos , Acetato de Medroxiprogesterona/farmacologia , Acetato de Medroxiprogesterona/uso terapêutico , Pessoa de Meia-IdadeRESUMO
Thyroid function was assessed in a total of 15 cases, 7 of whom had choriocarcinoma and 8 hydatidiform mole, by measuring free T3, free T4, thyroxin-binding globulin (TBG), basal thyroid-stimulating hormone (TSH) and after the thyrotropin-releasing hormone test (delta TSH). Free T3, free T4 and TBG were investigated in the same number of healthy women within the first three months of pregnancy. Only 13.4% of the cases presented elevated levels of free T3 and T4 and TBG; TSH and delta TSH were within normal limits. Both thyroid hormones and TBG returned to within normal limits when beta-human chorionic gonadotropin became undetectable. One patient was found to be hypothyroid. Comparison with the control group showed no significant differences except in TBG levels, which were higher in controls. A significant, direct correlation was found between levels of free T3 and T4 and TBG and the pattern of human chorionic gonadotropin.
